|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Ankylosing spondylitis (AS) is a rheumatic inflammatory disease with unknown etiology, and fatigue is one of the main systemic symptoms of AS.
|
31824954 |
2019 |
|
Ankylosing spondylitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is polygenic with contributions from the immunologically relevant genes HLA-B*27, ERAP1 and IL23R.
|
20463747 |
2010 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains elusive.
|
25994336 |
2015 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing Spondylitis Patients with HLA-B*2704 have More Uveitis than Patients with HLA-B*2705 in a North Chinese Population.
|
27428175 |
2018 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*2705 is strongly associated with ankylosing spondylitis (AS) and reactive arthritis.
|
10438975 |
1999 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*2702 is an ankylosing spondylitis-associated allotype that differs from the more common B*2705 at residues 77, 80, and 81, in the peptide-binding site.
|
11929585 |
2001 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*27 is known to be associated with ankylosing spondylitis and several methods have been applied to determine its presence or absence.
|
12366780 |
2002 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis, as defined by the Rome criteria, is present in 3-10% of inflammatory bowel disease patients, and is thought to have a different genetic predisposition in these patients compared with 'classic' ankylosing spondylitis: whereas the human leucocyte antigen B27 phenotype is present in 90% of patients with 'classic' ankylosing spondylitis, the prevalence decreases to only 30% in patients with ankylosing spondylitis secondary to Crohn's disease.
|
15352892 |
2004 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
HLA-B*2704, an allotype associated with ankylosing spondylitis, is critically dependent on transporter associated with antigen processing and relatively independent of tapasin and immunoproteasome for maturation, surface expression, and T cell recognition: relationship to B*2705 and B*2706.
|
17082617 |
2006 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Human leukocyte antigen-B*2705 is the predominant subtype in the Korean population with ankylosing spondylitis, unlike in other Asians.
|
18493767 |
2008 |
|
Ankylosing spondylitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HLA-B, DR and DQ antigens polymorphism in Tunisian patients with ankylosing spondylitis (a case-control study).
|
19655145 |
2010 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is the best characterised subset of AxSpA, and its genetic basis has been extensively investigated.
|
25956157 |
2016 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is an autoimmune disease with unknown etiology.
|
28182106 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is typically characterized by focal bone overgrowth and also by systemic bone loss.
|
28191455 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is a male-predominant disease, and radiographic evidence of damage is also more severe in males.
|
28882159 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is characterized by the formation of bony spurs.
|
28944904 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is characterized by osteoclastogenesis and inflammatory bone resorption.
|
29067128 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is a common chronic autoimmune disease characterized by inflammation of axial skeleton and has strong genetic susceptibility.
|
29207654 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is associated with an increased spinal fracture risk due to the loss of elasticity in spinal motion segments.
|
29288176 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is characterized by osteoproliferation-induced structural damage and spinal inflammation, which lead to spinal deformity and functional disability.
|
29299476 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing Spondylitis (AS) is a chronic, progressive, and inflammatory disease.
|
29308377 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is an immune-mediated arthritis which primarily affects the spine and sacroiliac joints.
|
29333268 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is a chronic autoimmune disease characterized by systemic inflammation and pathological osteogenesis.
|
29371928 |
2017 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis and autoimmune disease, the etiology and pathogenesis of which remain largely unknown.
|
29434723 |
2018 |
|
Ankylosing spondylitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is a common type of rheumatoid disease, which has recently been demonstrated to be associated with the expression of matrix metalloproteinase (MMP)-2.
|
29435070 |
2018 |